SG10201708215YA - Antibody and protein formulations - Google Patents
Antibody and protein formulationsInfo
- Publication number
- SG10201708215YA SG10201708215YA SG10201708215YA SG10201708215YA SG10201708215YA SG 10201708215Y A SG10201708215Y A SG 10201708215YA SG 10201708215Y A SG10201708215Y A SG 10201708215YA SG 10201708215Y A SG10201708215Y A SG 10201708215YA SG 10201708215Y A SG10201708215Y A SG 10201708215YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- protein formulations
- formulations
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/601,598 US8613919B1 (en) | 2012-08-31 | 2012-08-31 | High concentration antibody and protein formulations |
| US13/843,780 US9592297B2 (en) | 2012-08-31 | 2013-03-15 | Antibody and protein formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201708215YA true SG10201708215YA (en) | 2017-11-29 |
Family
ID=49162239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501116RA SG11201501116RA (en) | 2012-08-31 | 2013-08-28 | Antibody and protein formulations |
| SG10201708215YA SG10201708215YA (en) | 2012-08-31 | 2013-08-28 | Antibody and protein formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501116RA SG11201501116RA (en) | 2012-08-31 | 2013-08-28 | Antibody and protein formulations |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9592297B2 (en) |
| EP (3) | EP3590536A1 (en) |
| JP (3) | JP6462567B2 (en) |
| CN (2) | CN104684933B (en) |
| AR (2) | AR092388A1 (en) |
| AU (3) | AU2013308902B2 (en) |
| BR (1) | BR112015003838A2 (en) |
| CA (2) | CA2883095C (en) |
| CY (1) | CY1121989T1 (en) |
| DK (1) | DK3117837T3 (en) |
| ES (1) | ES2741575T3 (en) |
| HK (1) | HK1210794A1 (en) |
| HR (1) | HRP20191299T1 (en) |
| HU (1) | HUE045652T2 (en) |
| IL (6) | IL294567A (en) |
| LT (1) | LT3117837T (en) |
| MX (2) | MX369653B (en) |
| PL (1) | PL3117837T3 (en) |
| PT (1) | PT3117837T (en) |
| RS (1) | RS59221B1 (en) |
| RU (2) | RU2678097C2 (en) |
| SG (2) | SG11201501116RA (en) |
| SI (1) | SI3117837T1 (en) |
| TW (4) | TWI609697B (en) |
| UY (1) | UY34995A (en) |
| WO (1) | WO2014036071A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| MX2013011218A (en) * | 2011-04-01 | 2013-10-17 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi). |
| AT512589B1 (en) * | 2012-03-12 | 2014-06-15 | Zizala Lichtsysteme Gmbh | Light guide element for a laser vehicle headlight and vehicle headlights |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EP3808338A1 (en) | 2013-09-11 | 2021-04-21 | Eagle Biologics, Inc. | Liquid protein formulations containing ionic liquids |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| RU2021125449A (en) | 2014-10-01 | 2021-09-16 | Медиммьюн Лимитед | ANTIBODIES TO TICAGRELOR AND METHODS OF APPLICATION |
| WO2016054259A1 (en) | 2014-10-01 | 2016-04-07 | Arsia Therapeutics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| JP6664467B2 (en) | 2015-08-19 | 2020-03-13 | ファイザー・インク | Tissue factor pathway inhibitor antibodies and uses thereof |
| KR20200035496A (en) * | 2015-09-22 | 2020-04-03 | 화이자 인코포레이티드 | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
| WO2017180594A1 (en) * | 2016-04-13 | 2017-10-19 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| MX2018015960A (en) | 2016-06-30 | 2019-03-21 | Celltrion Inc | Stable liquid pharmaceutical preparation. |
| EP3484520A4 (en) * | 2016-07-13 | 2020-07-29 | Reform Biologics, LLC | Stabilizing excipients for therapeutic protein formulations |
| JP7170329B2 (en) | 2016-09-16 | 2022-11-14 | ロイコケア・アクチェンゲゼルシャフト | Novel methods for stabilization of biopharmaceutical products during processing |
| MY197200A (en) * | 2016-12-23 | 2023-05-31 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| KR20210029221A (en) * | 2018-07-05 | 2021-03-15 | 바이엘 악티엔게젤샤프트 | Method for producing freeze-dried pellets containing anti-coagulation factor XIa (FXIa) antibodies |
| KR102337683B1 (en) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | Highly efficient anti-TFPI antibody composition |
| MX2021004356A (en) * | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulations of anti-rsv antibodies and methods of use thereof. |
| CN111346225A (en) * | 2018-12-21 | 2020-06-30 | 上海张江生物技术有限公司 | Pharmaceutical formulations containing proteins |
| IL292493A (en) * | 2019-11-13 | 2022-06-01 | Pfizer | Stable aqueous anti-tfpi antibody formulation |
| WO2024026388A1 (en) * | 2022-07-27 | 2024-02-01 | Viela Bio, Inc. | Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4075193A (en) | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
| US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| ES2044941T5 (en) | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | STABILIZER OF GROWTH PROMOTING HORMONES. |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US4912861A (en) * | 1988-04-11 | 1990-04-03 | Huang Ing Chung | Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods |
| US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| WO1989011297A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| WO1990011091A1 (en) | 1989-03-27 | 1990-10-04 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
| JPH0565233A (en) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | Monoclonal antibody-containing lyophilized preparation |
| JP2966592B2 (en) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | Stabilized human monoclonal antibody preparation |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
| RU2143889C1 (en) | 1993-02-23 | 2000-01-10 | Генентек, Инк. | Method of stabilization of polypeptide, and methods of preparing polypeptide compositions |
| DE4344824C1 (en) | 1993-12-28 | 1995-08-31 | Immuno Ag | Highly concentrated immunoglobulin preparation and process for its preparation |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| AU716785B2 (en) | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
| DK0876140T3 (en) | 1996-01-25 | 2003-12-15 | Schering Ag | Improved contrast agent solutions for intravasal use |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| KR100236393B1 (en) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | A pharmaceutical preparation containing a human growth hormone |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| EP0852951A1 (en) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| EP1005776B1 (en) | 1997-08-21 | 2003-01-08 | Siemens Aktiengesellschaft | Method for transmitting user data that can be allocated to different applications |
| GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| JP2000247903A (en) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | Long-term stabilized pharmaceutical preparation |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| HU0800692D0 (en) | 1999-10-04 | 2009-01-28 | Novartis Vaccines & Diagnostic | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| AU2001236005A1 (en) | 2000-02-29 | 2001-09-12 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
| PT1272211E (en) | 2000-04-07 | 2007-09-14 | Signal Coordinating Therapy In | Methods and compositions for treating neoplasms |
| JP5490972B2 (en) | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | Protein injection formulation |
| WO2002013860A1 (en) | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| US7998929B2 (en) | 2000-09-01 | 2011-08-16 | Chugai Seikyaku Kabushiki Kaisha | Solution preparations stabilized over long time |
| DE60139944D1 (en) | 2000-10-12 | 2009-10-29 | Genentech Inc | LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| JP4317010B2 (en) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | Stable lyophilized pharmaceutical formulation of IgG antibody |
| BR0213298A (en) | 2001-10-16 | 2006-11-07 | Rxkinetix Inc | high protein formulations and manufacturing process |
| DK1441589T3 (en) | 2001-11-08 | 2012-08-06 | Abbott Biotherapeutics Corp | Stable, liquid, pharmaceutical composition of IgG antibodies |
| US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| WO2003062375A2 (en) | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| AU2003219958B2 (en) | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
| AU2005254062B2 (en) | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| US20060182740A1 (en) | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| AU2003251906B2 (en) | 2002-07-12 | 2008-12-04 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| PL211654B1 (en) | 2002-10-08 | 2012-06-29 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| NZ587852A (en) | 2002-12-24 | 2012-02-24 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| PT1610820E (en) | 2003-04-04 | 2010-12-16 | Novartis Ag | High concentration antibody and protein formulations |
| TWI382031B (en) | 2003-07-15 | 2013-01-11 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| JP4219932B2 (en) | 2003-10-01 | 2009-02-04 | 協和発酵キリン株式会社 | Antibody stabilization method and stabilized solution antibody preparation |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| JPWO2005063291A1 (en) | 2003-12-25 | 2007-07-19 | 麒麟麦酒株式会社 | Stable aqueous pharmaceutical formulations containing antibodies |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| KR20070107079A (en) | 2005-01-28 | 2007-11-06 | 와이어쓰 | Stabilized liquid polypeptide formulations |
| GT200600031A (en) * | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
| PT2620450T (en) | 2005-03-08 | 2018-12-17 | Pfizer Prod Inc | Anti-ctla-4 antibody compositions |
| CA2600601A1 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-m-csf antibody compositions having reduced levels of endotoxin |
| CN101166763B (en) * | 2005-04-18 | 2012-09-19 | 伊达研究和发展有限公司 | Stabilized anti-hepatitis B (HBV) antibody formulations |
| WO2007002543A2 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| ATE501248T1 (en) | 2005-07-02 | 2011-03-15 | Arecor Ltd | STABLE AQUEOUS SYSTEMS WITH PROTEINS |
| NZ623901A (en) | 2005-08-03 | 2015-10-30 | Immunogen Inc | Immunoconjugate formulations |
| AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| US20090169581A1 (en) | 2005-11-21 | 2009-07-02 | Cigarini Sandrine | Stabilizing formulations for recombinant viruses |
| EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | Antibody-containing stabilizing preparation |
| JP2009525986A (en) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | Protein preparation |
| DE102006005094A1 (en) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titanium dioxide and polycarboxylate ether-containing dispersion |
| EP2029163A4 (en) | 2006-06-14 | 2010-08-11 | Imclone Llc | Lyophilized formulations of anti-egfr antibodies |
| RU2499001C2 (en) | 2006-06-30 | 2013-11-20 | Ново Нордиск А/С | Antibodies to nkg2a and their applications |
| US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
| EP2094729A1 (en) | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
| JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン，エルエルシー | Antibody preparation |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| TWI614028B (en) | 2007-06-14 | 2018-02-11 | 百健Ｍａ公司 | Antibody formulations |
| CA2692165A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| UA107557C2 (en) | 2007-07-06 | 2015-01-26 | OFATUMUMAB ANTIBODY COMPOSITION | |
| JP5490714B2 (en) | 2007-11-28 | 2014-05-14 | メディミューン，エルエルシー | Protein preparation |
| TWI468174B (en) | 2007-12-14 | 2015-01-11 | Novo Nordisk As | Antibodies against human kng2d and uses thereof |
| ES2511844T3 (en) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Antibody formulation |
| BRPI0821600A2 (en) | 2007-12-28 | 2015-06-23 | Bioinvent Int Ab | Pharmaceutical composition, article of manufacture, kit of parts, method of combating atherosclerosis, or atherosclerosis-associated cardiovascular disease, and use of an antibody |
| RU2010138612A (en) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | HUMANIZED ANTIBODIES AGAINST C5aR |
| WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| KR20110039218A (en) | 2008-06-30 | 2011-04-15 | 노보 노르디스크 에이/에스 | Anti-human interleukin-20 antibodies |
| UA112050C2 (en) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI) |
| HUE036126T2 (en) | 2008-09-19 | 2018-06-28 | Pfizer | Stable liquid antibody formulation |
| RU2011126338A (en) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | STABLE COMPOSITIONS OF ANTIBODIES AND METHODS FOR THEIR STABILIZATION |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2009331570C1 (en) | 2008-12-22 | 2024-04-18 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
| RU2011151286A (en) | 2009-06-18 | 2013-07-27 | УАЙТ ЭлЭлСи | LYOPHILIZED RECIPES FOR SMALL MODULAR IMMUNOPHARMACEUTICAL PRODUCTS |
| EP2473527B1 (en) | 2009-09-03 | 2016-11-30 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| JP2013520476A (en) | 2010-02-26 | 2013-06-06 | ノヴォ ノルディスク アー／エス | Stable antibody-containing composition |
| SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2011108452A1 (en) * | 2010-03-02 | 2011-09-09 | Jnc株式会社 | Reduction reactor |
| CN103025345B (en) * | 2010-03-19 | 2016-01-20 | 巴克斯特国际公司 | TFPI inhibitor and using method |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| EP3354280B1 (en) * | 2010-10-06 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| MX2013011218A (en) | 2011-04-01 | 2013-10-17 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi). |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2013
- 2013-03-15 US US13/843,780 patent/US9592297B2/en active Active
- 2013-08-28 DK DK16180643.5T patent/DK3117837T3/en active
- 2013-08-28 HU HUE16180643A patent/HUE045652T2/en unknown
- 2013-08-28 RU RU2015111341A patent/RU2678097C2/en not_active IP Right Cessation
- 2013-08-28 RS RSP20190976 patent/RS59221B1/en unknown
- 2013-08-28 RU RU2019100887A patent/RU2019100887A/en not_active Application Discontinuation
- 2013-08-28 SG SG11201501116RA patent/SG11201501116RA/en unknown
- 2013-08-28 EP EP19175217.9A patent/EP3590536A1/en not_active Ceased
- 2013-08-28 PT PT16180643T patent/PT3117837T/en unknown
- 2013-08-28 IL IL294567A patent/IL294567A/en unknown
- 2013-08-28 JP JP2015529977A patent/JP6462567B2/en active Active
- 2013-08-28 CN CN201380051319.0A patent/CN104684933B/en active Active
- 2013-08-28 ES ES16180643T patent/ES2741575T3/en active Active
- 2013-08-28 WO PCT/US2013/056970 patent/WO2014036071A1/en active Application Filing
- 2013-08-28 PL PL16180643T patent/PL3117837T3/en unknown
- 2013-08-28 SG SG10201708215YA patent/SG10201708215YA/en unknown
- 2013-08-28 BR BR112015003838A patent/BR112015003838A2/en not_active Application Discontinuation
- 2013-08-28 US US14/421,607 patent/US20150209431A1/en not_active Abandoned
- 2013-08-28 CA CA2883095A patent/CA2883095C/en active Active
- 2013-08-28 IL IL286784A patent/IL286784B/en unknown
- 2013-08-28 EP EP16180643.5A patent/EP3117837B1/en active Active
- 2013-08-28 MX MX2015002411A patent/MX369653B/en active IP Right Grant
- 2013-08-28 CA CA3129277A patent/CA3129277A1/en active Pending
- 2013-08-28 EP EP13760179.5A patent/EP2890718A1/en not_active Withdrawn
- 2013-08-28 LT LTEP16180643.5T patent/LT3117837T/en unknown
- 2013-08-28 AU AU2013308902A patent/AU2013308902B2/en not_active Ceased
- 2013-08-28 CN CN202111330122.3A patent/CN114392353A/en active Pending
- 2013-08-28 SI SI201331538T patent/SI3117837T1/en unknown
- 2013-08-29 AR ARP130103085A patent/AR092388A1/en unknown
- 2013-08-29 UY UY0001034995A patent/UY34995A/en not_active Application Discontinuation
- 2013-08-30 TW TW102131180A patent/TWI609697B/en not_active IP Right Cessation
- 2013-08-30 AR ARP130103099A patent/AR092400A1/en unknown
- 2013-08-30 TW TW102131326A patent/TW201414496A/en unknown
- 2013-08-30 TW TW108113538A patent/TW201927338A/en unknown
- 2013-08-30 TW TW106131685A patent/TW201825116A/en unknown
- 2013-12-16 US US14/107,658 patent/US20140105892A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,408 patent/US9849181B2/en active Active
-
2015
- 2015-02-11 IL IL237188A patent/IL237188A0/en unknown
- 2015-02-24 MX MX2019013670A patent/MX2019013670A/en unknown
- 2015-11-27 HK HK15111675.2A patent/HK1210794A1/en unknown
-
2017
- 2017-08-16 US US15/679,053 patent/US20180055940A1/en not_active Abandoned
- 2017-10-18 US US15/787,610 patent/US20180028669A1/en not_active Abandoned
-
2018
- 2018-05-11 AU AU2018203320A patent/AU2018203320B2/en not_active Expired - Fee Related
- 2018-12-17 JP JP2018235273A patent/JP2019048886A/en active Pending
-
2019
- 2019-04-07 IL IL265864A patent/IL265864B/en active IP Right Grant
- 2019-04-07 IL IL265865A patent/IL265865A/en unknown
- 2019-07-18 HR HRP20191299TT patent/HRP20191299T1/en unknown
- 2019-08-16 CY CY20191100881T patent/CY1121989T1/en unknown
-
2020
- 2020-01-08 AU AU2020200134A patent/AU2020200134A1/en not_active Abandoned
- 2020-11-11 US US17/095,102 patent/US20230190637A9/en not_active Abandoned
- 2020-12-06 IL IL279237A patent/IL279237A/en unknown
-
2021
- 2021-01-13 JP JP2021003390A patent/JP2021059602A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286784A (en) | Antibody and protein formulations | |
| HK1243344A1 (en) | Antibody formulations and methods | |
| HRP20190358T1 (en) | Anti-asic1 antibodies and uses thereof | |
| HK1210714A1 (en) | Antibody formulations and uses thereof | |
| HK1207654A1 (en) | Modified antibody regions and uses thereof | |
| ZA201405554B (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EP2930189A4 (en) | Chemokine-cytokine fusion protein and application thereof | |
| GB201208372D0 (en) | Antibodies and uses thereof |